Market cap
₹12 Cr
Revenue (TTM)
₹73 Cr
P/E Ratio
29.8
P/B Ratio
0.5
Div. Yield
0 %
| Ishan Intl | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
12 | 11,328 | 259 | 224 | 62 |
Revenue (₹ Cr) |
73 | 23,506 | 82 | 434 | 173 |
Net Profit (₹ Cr) |
0.21 | 553.62 | 10.62 | 17.44 | 2.28 |
Net Margin (%) |
0.29 | 2.35 | 12.59 | 3.90 | 1.27 |
RoE (%) |
0.93 | 10.18 | 9.30 | 6.80 | 2.31 |
Price to Earnings |
29.81 | 20.46 | 24.37 | 12.87 | 28.70 |
Price-To-Book |
0.53 | 1.82 | 2.08 | 0.86 | 0.51 |
Income Statement (₹ Cr)
| Ishan Intl | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Operating Revenue
|
72.65 | 21,846.70 | 68.91 | 443.18 | 130.23 |
|
Total Income
|
73.55 | 21,932.08 | 70.30 | 453.72 | 133.35 |
|
Total Expenditure
|
72.56 | 20,181.97 | 54.24 | 417.48 | 123.85 |
|
EBITDA
|
0.10 | 1,664.73 | 14.67 | 25.70 | 6.38 |
|
Depreciation
|
0.15 | 183.68 | 4.75 | 10.87 | 3.37 |
|
EBIT
|
-0.06 | 1,481.05 | 9.91 | 14.83 | 3.01 |
|
Interest
|
0.55 | 838.94 | 0.78 | 12.35 | 11.88 |
|
Other Income
|
0.90 | 85.38 | 1.40 | 10.54 | 3.13 |
|
Exceptional Items
|
-- | -- | -- | 11.95 | -- |
|
Profit before Tax
|
0.29 | 727.49 | 10.53 | 24.98 | -5.74 |
|
Provision for Tax
|
0.07 | 156.75 | 2.82 | -1.74 | 0.36 |
|
Profit after Tax
|
0.21 | 570.74 | 7.71 | 26.72 | -6.11 |
Liabilities (₹ Cr)
| Ishan Intl | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
22.58 | 5,347.45 | 113.60 | 245.18 | 72.51 |
|
Minority Interest
|
-- | -- | -- | -- | 27.41 |
|
Non-Current Liabilities
|
0.30 | 152.89 | 2.47 | 57.83 | 65.54 |
|
Current Liabilities
|
46.54 | 16,226.88 | 10.58 | 219.44 | 102.48 |
|
Total Liabilities
|
69.77 | 22,164.37 | 127.18 | 526.89 | 267.94 |
Assets (₹ Cr)
| Ishan Intl | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
6.78 | 2,340.58 | 68.69 | 311.28 | 90.00 |
|
Current Assets
|
62.65 | 19,386.64 | 57.96 | 211.18 | 177.94 |
|
Total Assets
|
69.77 | 22,164.37 | 127.18 | 526.89 | 267.94 |
|
Total Debt*
|
6.07 | 3,701.10 | 6.35 | 139.02 | 137.07 |
|
Net Current Assets
|
16.10 | 3,159.76 | 47.38 | -8.27 | 75.45 |
|
Contingent Liabilities
|
0.02 | 179.24 | 2.63 | 15.96 | -- |
Cashflow (₹ Cr)
| Ishan Intl | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-0.29 | 419.07 | 11.60 | 7.70 | -6.74 |
|
Cash Flow from Investing Activities
|
0.16 | -67.87 | -11.76 | -6.56 | 24.74 |
|
Cash from Financing Activities
|
-1.87 | -32.12 | 1.84 | -2.92 | -18.30 |
|
Net Cash Inflow / Outflow
|
-2.00 | 319.08 | 1.67 | -1.78 | -0.29 |
Ratios
Profitability Ratios
| Ishan Intl | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
ROCE (%)
|
2.87 | 18.50 | 9.72 | 10.22 | 3.19 |
|
ROE (%)
|
0.93 | 12.09 | 6.90 | 11.55 | -9.25 |
|
ROA (%)
|
0.26 | 2.83 | 6.11 | 5.30 | -2.44 |
|
EBIT Margin (%)
|
1.36 | 8.01 | 23.31 | 8.18 | 7.30 |
|
Net Margin (%)
|
0.29 | 2.60 | 10.97 | 5.89 | -4.58 |
|
Cash Profit Margin (%)
|
0.51 | 3.45 | 18.10 | 8.46 | -2.10 |
Growth Ratios
| Ishan Intl | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
141.14 | 9.70 | -8.20 | 21.99 | -21.66 |
|
EBIT Growth (%)
|
-38.07 | 24.26 | 4.40 | 281.35 | -61.80 |
|
Net Profit Growth (%)
|
-62.45 | 64.58 | 2.50 | 154.96 | -158.60 |
|
EPS Growth (%)
|
-62.64 | 58.96 | 2.50 | 154.96 | -124.45 |
|
Book Value Growth (%)
|
-4.75 | 30.56 | 3.36 | 12.75 | 9.39 |
Valuation Ratios
| Ishan Intl | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Price / Earnings
|
90.91 | 36.50 | 18.31 | 7.69 | 0.00 |
|
Price / Book Value
|
0.86 | 3.90 | 1.24 | 0.84 | 0.86 |
|
Dividend Yield (%)
|
0.00 | 0.70 | 0.70 | 0.00 | 0.00 |
|
EV/EBITDA
|
22.91 | 13.64 | 7.77 | 9.48 | 21.23 |
|
Market Cap (₹ Cr)
|
19.46 | 20,830.83 | 141.26 | 205.41 | 64.93 |
Solvency Ratios
| Ishan Intl | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.27 | 0.69 | 0.06 | 0.57 | 1.99 |
|
Short term debt to equity ratio
|
0.25 | 0.60 | 0.03 | 0.41 | 0.97 |
|
Current Ratio
|
1.35 | 1.19 | 5.48 | 0.96 | 1.74 |
|
Quick Ratio
|
1.35 | 1.12 | 4.20 | 0.54 | 1.33 |
|
Interest Coverage
|
1.53 | 1.87 | 14.57 | 3.02 | 0.52 |
Operating Efficiency Ratios
| Ishan Intl | KEC International | Tamboli Capital | Gillanders Arbuthnot | Indrayani Biotech | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
8.00 | 23.12 | 23.68 | 13.95 | 45.07 |
|
Asset Turnover
|
0.87 | 1.08 | 0.55 | 0.88 | 0.52 |
|
Receivable days
|
50.71 | 76.75 | 91.99 | 37.44 | 137.64 |
|
Inventory Days
|
1.90 | 19.66 | 67.73 | 76.25 | 117.29 |
|
Payable days
|
120.92 | 237.22 | 166.81 | 124.30 | 134.44 |
|
Cash Conversion Cycle
|
-68.31 | -140.81 | -7.10 | -10.61 | 120.49 |